Prof. Dr. Alten completed her training in Internal Medicine at the Free University Berlin, followed by training in Rheumatology in Zürich. This cookie is set by LinkedIn and used for routing. Steven Simoens has conducted biosimilar research sponsored by Hospira (now Pfizer); was involved in a stakeholder roundtable on biosimilars sponsored by Amgen, MSD, and Pfizer; has participated in an advisory board meeting for Pfizer; and currently works with Amgen, Celltrion, Mundipharma, and Pfizer as a consultant to carry out biosimilar research. Accessibility The department strictly adheres to all the requirements of professional societies, which is the key to a successful therapy result. CI, confidence interval. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. HHS Vulnerability Disclosure, Help -, Pharmacoeconomics. We note with interest that Dr. Lionel Roger has written concerning evening application of triamcinolone to treat rheumatoid arthritis (RA)1. HMC is the principal public healthcare provider in the State of Qatar, delivering the safest, most effective and most compassionate care to each and every one of our patients. This session cookie is served by our membership/subscription system and controls which types of content you are able to access. Baseline demographic characteristics of the evaluable patients were similar between patients in either line-of-treatment group (Table 1). The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Email: Rieke.Alten@schlosspark-klinik.de; Tel: +49 30 3264-1325; Fax: +49 30 3264-1324 Running header: Treatment failure psoriatic arthritis Manuscript main body Click here to access/download;Manuscript;Alten et al._Unmet Received 2013 Sep 3; Accepted 2014 Jan 2. Patient clinical characteristics by line-of-treatment group are summarized in Table 1. Du Pan SM, Scherer A, Gabay C, Finckh A. SAEs were reported in 4.7% (n = 54/1138) of patients and discontinuations due to SAEs occurred in 1.8% (n = 20/1138) of patients. Patients receiving abatacept earlier in the course of treatment (ie, first-line) achieved numerically greater mean changes from baseline in HAQ-DI compared with second-line abatacept (−0.44, [95% CI: –0.58, –0.29] versus −0.29 [95% CI: –0.34, –0.24], respectively), although 95% CIs overlapped. 8600 Rockville Pike She has served as board member of the German Medical Association, the Institute for Approval of Drugs for the German Ministry of Health, the “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and the German Society of Rheumatology. 2020 May;6(1):e001223. FR made a substantial contribution to the acquisition of data. For biologics shown in. 2016;14:1685–1696. PMI has received honoraria for acting in an advisory capacity from AbbVie, Celgene, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Samsung Bioepis, Sandoz, Takeda, Topivert, VH2, Vifor, and Warner Chilcott; received speaker fees from AbbVie, Falk Pharma, Ferring, Janssen, MSD, Pfizer, Sandoz, Shire, Takeda, Tillotts, and Warner Chilcott; and received research funding from MSD, Pfizer, and Takeda. More than 67% of patients achieved a good or moderate EULAR response, as defined by DAS28 (ESR) or DAS28 (CRP) independently of whether abatacept was initiated as first- or second-line therapy (Figure 4). 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4. Armuzzi A, Avedano L, Greveson K, Kang T. J Crohns Colitis. Of note was the high retention rate for biologic-naïve patients in the current study (93.0%), which is consistent with evidence from abatacept RCTs showing that patient retention is higher when abatacept is initiated earlier in the treatment regimen [11,14]. In IBD, the cost-effectiveness of biologic treatment earlier in the disease course is likely to improve when biosimilars are incorporated into pharmacoeconomic analyses. The proportions of patients achieving LDAS or remission are shown in Figure 3A–C. 1975 Doctoral thesis, Faculty of Medicine, University of Zurich. Rieke H. E. Alten works at Academic Hospital Schlosspark Charlottenburg Berlin. The results of the double-blind study phase comparing the modified-release and the immediate-release tablets and the subsequent 9-month open-label treatment phase with the modified-release tablet are reported in the 2 previous publications on the CAPRA-1 study3,4. This cookie is set by Youtube and is used to track the views of embedded videos. The incidence of SAEs was 4.7%. D. Boumpas has nothing to disclose. This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. F. Rainer has nothing to disclose. The percentage of patients achieving CDAI LDAS was 40.0% (95% CI: 26.4, 53.6) for first- and 32.2% (95% CI: 28.4, 36.0) for second-line patients and the proportion achieving a HAQ-DI response was 60.3% (95% CI: 47.8, 72.9) versus 43.1% (95% CI: 39.0, 47.2), respectively. This site needs JavaScript to work properly. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, Dougados M. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. This cookie is set by LinkedIn and is used for tracking. Conaghan PG, Alten R, Deodhar A, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Strand V. RMD Open. Of 1138 enrolled patients, 1114 (97.9%) were evaluable for the descriptive analysis and retention rate calculation. Taylor PC, Gonzalez YS, Clark R, Faccin F, Howell O. Rheumatol Ther. 2023 May 1;6(5):e2315872. Retention rates reported in the current trial were high – >80.0% for second-line and 93.0% for first-line patients – compared with evidence from other real-world observational studies. Reviews "Besonders wertvoll ist dieses Buch durch die zahlreichen Illustrationen [.] Expert Rev Gastroenterol Hepatol. A sensitivity analysis was conducted on data from patients for whom both DAS28 and CDAI assessments were available and showed that the effectiveness outcomes at Month 6 in these patients were similar to those in the overall population. Website development by e-Motive Media Limited. Thank you for your interest in spreading the word about The Journal of Rheumatology. The primary specialization of the doctor is internal medicine, rheumatology and immunology, osteology. phone email Contact. A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 6-Month Effectiveness and Patient Reported Outcome Data from the European Cohort [abstract]. NCI CPTC Antibody Characterization Program, Health Policy. The majority of patients were at high risk of disease progression: 58.0% in the first-line group and 71.4% in the second-line group had erosions, 59.0% of first-line and 65.9% of second-line patients were anti-cyclic citrullinated protein positive, and 68.1% in the first-line and 69.3% in the second-line group were rheumatoid factor (RF) positive. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. 1984 Board certification in Internal Medicine. All Rights Reserved. Contact Rieke, search articles and Tweets, monitor coverage, and track replies from one place. Patients were enrolled prospectively between May 2008 and January 2011, either on, or within 3 months of, initiating treatment with abatacept according to the Summary of Product Characteristics (SmPC) in Europe and the Product Monograph in Canada. Lucasson F, Kiltz U, Kalyoncu U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Meisalu S, Ryussen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Richette P, Husni E, Coates LC, de Wit M, Smolen JS, Orbai AM, Gossec L. RMD Open. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Evidence from the Swedish national registry ARTIS showed that, 1 year after initiating abatacept treatment, retention rates were 80% for biologic-naïve patients and 64% for patients previously treated with 1–2 biologics [17]. This cookie is set by LinkedIn. Safety was presented for the entire enrolled population, regardless of prior or concomitant treatment. Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, Sarzi-Puttini P, Atzeni F, Montecucco C. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Moreover, the decision to treat a patient with abatacept was made before their enrollment in the study. 8600 Rockville Pike G.R. DOI: https://doi.org/10.3899/jrheum.110114, Where in the world is oral triamcinolone? Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Among second-line patients, a numerically higher proportion of patients who failed one prior anti-TNF had achieved LDAS and remission, for all three composite scales, compared with patients who had failed ≥2 prior anti-TNFs although 95% CIs overlapped (Table 3). Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns? (B) Kaplan–Meier curves based on reasons for discontinuation of prior biologic therapy are shown for patients who discontinued due to primary inefficacy, secondary inefficacy, or safety and tolerability reasons. This byline is for a different person with the same name. Analysis of abatacept effectiveness overall, and stratified by line of therapy, and by number of previous failed anti-TNFs. In addition, response and remission rates with abatacept in the ACTION study were similar to those reported in the two previously mentioned abatacept RCTs in patients with a prior inadequate response to anti-TNF agents, the ATTAIN [13] and ARRIVE studies [32]. This website uses cookies to improve your experience while you navigate through the website. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Similar proportions of patients from both groups presented with at least one comorbidity at enrollment; most commonly metabolic disorders (26.8%, n = 298), including lipid metabolism and deposit disorders (not elsewhere classified [15.9%, n = 177]), and diabetes (12.1%, n = 135); endocrine disorders (14.2%, n = 158), including hypothyroidism (10.1%, n = 112); respiratory disease (10.1%, n = 113); and cardiac disorders (6.4%, n = 71). Although retention rates for RCTs are expected to be higher than for real-world studies [7], the retention rates in the current study were consistent with an 82–90% retention rate reported from two abatacept RCTs, the ATTAIN and ARRIVE studies [13,32]. 1989 Board certification in Physiotherapy. Among those who were on concomitant corticosteroids at abatacept initiation and for whom 6-month data were available, 39/555 (7.0%) of patients discontinued all corticosteroids from initiation to 6 months, and 141/462 (30.5%) patients had a dose decrease from 10 mg/day (median dose at initiation) to 5 mg/day (median dose at 6 months). et al. Health-related quality of life; Psoriatic arthritis; TNFi; Treatment; Work. The ACTION study was conducted in accordance with the Declaration of Helsinki and was consistent with the International Conference on Harmonization Good Clinical Practice Guidelines [20] and Good Epidemiological Practice Guidelines [21]. 2005 Additional qualifications in Osteology (German Society of Osteology). Kim DW, Lee Y, Kim G, Kim SH, Cho DH, Choi J, Kwon YH, Park Y, Choi W, Park DI. Please view our. Drugs. Patients currently failing immunomodulator therapies (n = 246) had poorer HRQoL compared with treatment success (n = 1472) measured by EQ-5D-3L (0.60 vs 0.77%; P < 0.0001); SF-36 PCS (40.8% vs 46.1%; P < 0.0001) MCS (41.1% vs 45.3%; P < 0.0001). doi: 10.1136/rmdopen-2021-002031. The .gov means it’s official. Dr. Roger responded to our article on chronotherapy of RA with a new modified-release prednisone tablet . Proportion of patients with LDAS* or remission at baseline and at Month 6 for second line abatacept stratified by 1 or ≥2 prior anti-TNF agent. 2022 Aug 17;6(1):49. doi: 10.1186/s41927-022-00279-7. *Includes patients receiving abatacept as a second- or further-line of treatment. Effectiveness was measured using European League Against Rheumatism (EULAR) response criteria, the 28-item Disease Activity Score, the Clinical Disease Activity Index (CDAI), and physical function, as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI). Furthermore, increased proportions of patients achieved remission or LDAS after 6 months of abatacept treatment following the failure of <2 anti-TNF agents, compared with those who had failed ≥2 anti-TNF agents. The objective of this report is to present a 6-month interim analysis of the data from the ACTION (AbataCepT In rOutiNe clinical practice) study, a 2-year prospective, observational cohort study that enrolled patients with RA in Europe and Canada to evaluate patient retention and the effectiveness of treatment with abatacept in routine clinical practice. Abatacept was initiated in combination with corticosteroids in 74.9% (n = 746) of patients in the second-line treatment group. 1975 - 1984 Research Fellow, Internal Medicine, Free University of Berlin. Similarly, 6-month retention rates with abatacept treatment were 72.0% in the Danish DANBIO registry [16] and 80.0% in a US observational study [18]. RMD Open. Deodhar A, Strand V, Conaghan PG, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Alten R. BMC Rheumatol. Previous studies have demonstrated that abatacept may have an impact on efficacy measures as early as 7 days from the first infusion [22]. PMC Of 1138 consecutively enrolled patients, 1114 and 1079 patients were evaluable for retention and effectiveness, respectively. Since 1998 President of the Society of Psychosomatics in Rheumatology. Gender and previous treatment influence outcomes from abatacept in a 5-year rheumatoid arthritis cohort [Abstract]. Federal government websites often end in .gov or .mil. National Library of Medicine Serious infections were reported in 1.7% (n = 19) of patients. official website and that any information you provide is encrypted Objective There are limited data on therapy selection and switching in psoriatic arthritis (PsA). Accessibility Abatacept was initiated in combination with corticosteroids in 64.4% (n = 76) of first-line patients. Among second-line patients, mean changes from baseline in DAS28 (ESR), DAS28 (CRP), and CDAI were numerically greater among those who failed one prior anti-TNF and those who failed ≥2, but with overlapping 95% CI (Table 2). The current interim analysis evaluated a 6-month dataset from this ongoing 2-year study. Switching biologics in the treatment of psoriatic arthritis. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. SD has received consulting fees or honorarium from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring Pharmaceuticals Inc., Gilead, Hospira, Janssen, Johnson & Johnson, MSD, Mundipharma, and Pfizer. Physical functioning, activity, and work productivity were also more impaired (HAQ-DI: 0.88 vs 0.56; activity impairment: 46.7% vs 29.7%; overall work impairment: 35.4% vs 26.1%; all P < 0.0001). government site. Biosimilars-biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators-can stimulate market competition and have the potential to expand patient access to biologics within the parameters of treatment recommendations. Hubert G Nüßlein, 1 Rieke Alten, 2 Mauro Galeazzi, 3 Hanns-Martin Lorenz, 4 Dimitrios Boumpas, 5 Michael T Nurmohamed, 6 William G Bensen, 7 Gerd R Burmester, 8 Hans-Hartmut Peter, 9 Franz Rainer, 10 Karel Pavelka, 11 Melanie Chartier, 12 Coralie Poncet, 13 Christiane Rauch, 14 and Manuela Le Bars 15 The efficacy, safety, and tolerability of abatacept for the treatment of moderate-to-severe RA have been demonstrated in RCTs [10-14], in local national registries [15,16], and in a small, single-site observational study [18]. This observational study did not interfere with a physician’s routine clinical practice. Unable to load your collection due to an error, Unable to load your delegates due to an error, Biologics licensed by the FDA and/or EMA for the treatment of RA and/or IBD as of 25 November 2019 (references are provided in Table S2 in the electronic supplementary material). sharing sensitive information, make sure you’re on a federal Please enable it to take advantage of the complete set of features! Curriculum vitae of Prof. Dr. med. Best Pract Res Clin Gastroenterol. H.-H. Peter has nothing to disclose. http://creativecommons.org/licenses/by/2.0, Previously treated with biologic agents, n (%), Number of prior anti-TNF agents, mean (SD), Patient global assessment, mean (SD) (VAS 100 mm), Physician global assessment, mean (SD) (VAS 100 mm), Patient global assessment of pain, mean (SD) (VAS 100 mm). Kent D, Rickwood S, and Di Biase S. Disruption and maturity: the next phase of biologics. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Current Medication Practices and Preferences Among Patients With Psoriatic Arthritis. This is used to present users with ads that are relevant to them according to the user profile. Nor can we give an answer to his leading question, “where in the world is oral triamcinolone.” Triamcinolone plays an undisputed role in topical administration of glucocorticoids, such as in the form of crystalline suspensions for intraarticular injections. Recent data suggest that when treatment with an anti-TNF agent shows lack of efficacy, switching to a biologic agent with a different mechanism of action may be of benefit [6]. This cookie is set by Advanced Ads and measures the number of previous page impressions. doi: 10.1016/j.autrev.2018.12.009. Rieke Alten 1 , P G Conaghan 2 , V Strand 3 , E Sullivan 4 , S Blackburn 4 , H Tian 5 , K Gandhi 5 , S M Jugl 6 , A Deodhar 7 Affiliations 1 Internal Medicine II, Rheumatology bei Schlosspark-Klinik, University Medicine, Berlin, Germany. 1216: Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study, 1745: A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Techniques, Innovation Theater: Women Leaders in Rheumatology: Exploring Leadership Paths. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL. In addition, the data suggest that patients treated earlier in their disease course with abatacept have better outcomes than patients treated after failure of one or more anti-TNF agents. (A) Kaplan–Meier curves for the overall patient population, the first-line group and the second-line group. Poor treatment response in PsA is associated with substantial negative patient impact. She has been the lead investigator in clinical trials of novel therapies in rheumatic diseases and has contributed to several investigator-initiated trials. Used to track the information of the embedded YouTube videos on a website. 1975 - 1984 Department of Internal Medicine (focus on rheumatism treatment), Immanuel Hospital, Berlin. 2022 Mar 1;28(2):55-61. doi: 10.1097/RHU.0000000000001799. © Russell Publishing Limited, 2010-2023. and transmitted securely. The findings presented here underline that abatacept, when used alone or in combination with DMARDs, provides a well-tolerated and effective treatment option for patients with RA, including those for whom previous anti-TNF treatment has failed. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B. At the time of this analysis, approximately 86% of patients had outcomes at Month 6 and 14% had either been lost to follow-up at the data cut-off or their documentation had not been received. (A) Assessed by the DAS28 (ESR), (B) by the DAS28 (CRP), and (C) by the CDAI. You also have the option to opt-out of these different types of cookies. Changes in disease state were assessed using the DAS28 (ESR), DAS28 (CRP), and CDAI scores for patients in the overall population with data evaluable for effectiveness at baseline and Month 6. Remission was defined as a DAS28 score <2.6 or a CDAI score ≤2.8. She served as board member of German Medical Association, as member of the Institute for Approval of drugs for the German Ministry of Health. and transmitted securely. Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Help; Gift Cards; Events; Educators; Millionaire's Club; menu Department of Rheumatology.Academic Hospital Schlosspark Berlin: Within 1 working day, a medical advisor will study your request and contact you by phone (German or your local number will be displayed). Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. This cookie is set by Spotler and stores the UTM values for the session. As a library, NLM provides access to scientific literature. Functional impairment measurement in psoriatic arthritis: Importance and challenges. This is demonstrated in several large cohort and retrospective studies by longer retention rates for first treatment courses versus subsequent courses (hazard ratio: 2.17; 95% confidence interval [CI]: 1.72, 2.58) and decreased median drug survival times for subsequent anti-TNF agents (37 months for first-line agent to 13 months for third-line agent) [3,5]. This interim analysis was also vulnerable to missing data as none of the study assessments were mandatory; thus, most missing clinical outcome data may have been attributed to assessments not performed routinely at all locations. and transmitted securely. T: +44 (0)1959 563311 Indeed, anti-TNF therapy discontinuation rates in real-world practice are about 30%, based on cohort studies with median follow-up of 15–37 months [2,3]. Overall, patients in both treatment groups had high levels of disease severity at baseline according to DAS28 (ESR), CDAI, and HAQ-DI scores (Table 1). Among patients for whom data were available at Month 6, the mean (SD) baseline HAQ-DI was 1.5 (0.6), and the mean change in HAQ-DI score from baseline to Month 6 was −0.30 (95% CI: –0.35, –0.26). For patients in the second-line group, the Kaplan–Meier estimated retention rate at endpoint (Day 169/Month 6) for patients initiating abatacept treatment after >1 prior failed anti-TNF treatment was 89.2% (95% CI: 85.8, 91.8) and for those who had failed ≥2 anti-TNF therapies it was 86.7% (95% CI: 83.1, 89.5). This cookie is set by GDPR Cookie Consent WordPress Plugin. The https:// ensures that you are connecting to the M. Chartier is a consultant for Bristol-Myers Squibb. Regulators and developers should collaborate to ensure biosimilars reach patients rapidly without compromising stringent quality, safety, or efficacy standards. 2020 Mar 2;4:19. doi: 10.1186/s41927-020-0118-z. Conclusions: Here we present a 6-month interim analysis of a 2-year prospective observational trial in Europe and Canada aiming to assess the real-world effectiveness, safety, and tolerability of intravenous abatacept for the treatment of moderate-to-severe RA. Keywords: 2022 Jul 31;7:100162. doi: 10.1016/j.rcsop.2022.100162. The authors would like to thank all physicians who participated in the ACTION study. This cookie is set by Spotler and tracks an anonymous visitor ID. Disclaimer. Dr. Roger responded to our article on chronotherapy of RA with a new modified-release prednisone tablet with a special focus on the adrenal function tests2. HK is employed by and holds stock options in Celltrion Healthcare Co., Ltd. LA has received financial support from Biogen for lectures; grants have been awarded to the European Federation of Crohn’s & Ulcerative Colitis Associations (for projects, advocacy activities, surveys) from Atlantic, AbbVie, Biogen, Celgene, Celltrion, Merck-MSD, Ferring, Janssen, Mundipharma, Otsuka, Pfizer, Shire, Takeda, Vifor, and Philips Morris International Foundation. *All patients with relevant baseline data assessed no later than 8 days after the first infusion of abatacept. This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users. Among second-line patients, the mean change from baseline in HAQ-DI (−0.35 [95% CI: –0.42, –0.28] versus −0.23 [95% CI: –0.29, –0.17]) and the proportion of patients achieving a HAQ-DI response (48.5 [95% CI: 42.6, 54.5] versus 37.1% [95% CI: 31.4, 42.8]) were greater among those who failed one prior anti-TNF compared to those who failed ≥2. This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site. View the profiles of professionals named "Rieke Alten" on LinkedIn. No formal assessment was performed to define reasons for prior treatment failure, other than those reported by the treating physician. Sign In to Email Alerts with your Email Address. Retention rates were calculated using Kaplan–Meier curve estimates. Register No. Developers must operate efficiently to be sustainable, without undermining product quality, the reliability of the supply chain, or pharmacovigilance. Patients who had their clinical assessment more than 8 days after their first abatacept infusion were not included in the effectiveness analysis. Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study. Dr. Roger’s experience with evening dosing of triamcinolone and his appeal that European League Against Rheumatism and American College of Rheumatology study groups should “request from the pharmaceutical industry” an immediate reintroduction of oral triamcinolone is understandable. Patients could report more than one reason for discontinuation of prior treatment before study enrollment. YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in . The cookie is a session cookies and is deleted when all the browser windows are closed. Lack of efficacy with first immunomodulatory therapy was the most common reason for switching; patients whose physicians indicated "primary lack of efficacy" as the reason, switched after a mean of 9.4 months. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. Address correspondence to Dr. Alten; E-mail: rieke.alten{at}schlosspark-klinik.de. Before It provides the treatment of all systemic rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, collagenoses, vasculitides and spondyloarthropathy. Joseph’s Hospital/McMaster University, Hamilton, Ontario, Canada, 8Charité-Universitätsmedizin Berlin, Berlin, Germany, 9University Medical Center Freiburg, Freiburg, Germany, 10Hospital Barmherzige Brueder, Graz, Austria, 11Institute of Rheumatology and Clinic of Rheumatology, Charles University, Prague, Czech Republic, 12Chiltern International, Neuilly, France, 15Bristol-Myers Squibb, Rueil-Malmaison, France. 0000977769. Careers. Prof. Dr. Rieke Alten is Head of the Department of Internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik, University Medicine Berlin, where she also serves as the Director of the Rheumatology Research Center. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Among the 974 patients for whom reasons for discontinuation of the prior biologic before study enrollment were available, the reasons were: primary inefficacy (26.6%, n = 259), loss of efficacy (secondary inefficacy) (46.5%, n = 453), safety and tolerability (22.0%, n = 214), other unspecified reasons (5.6%, n = 55), and achieving remission or experiencing a major improvement (0.5%, n = 5).
Kind Klagt über Kopfschmerzen Und Bauchschmerzen, Infraspinatus Entzündung Symptome, Fotogeschenk Enkelkinder, ü40 Party, Dresden Heute, Articles R